Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614376 | 0.96 | F10 (0.46) | F10KLKB1NAMPTNT5EKMT2A | |
| SCHEMBL13546151 | 0.91 | NPC1 (0.48) | F10NAMPTKMT2AMAPK1MAPT | |
| SCHEMBL8244509 | 0.87 | F10 (0.52) | F10KLKB1KMT2AMAPK1MAPT | |
| SCHEMBL4668469 | 0.85 | F10 (0.46) | F10KMT2AMAPTHTTSMN1; SMN2 | |
| SCHEMBL4664887 | 0.85 | F10 (0.43) | F10KLKB1KMT2ALMNACYP11B1 | |
| SCHEMBL3621342 | 0.83 | F10 (0.51) | F10KLKB1KMT2AMAPK1MAPT | |
| SCHEMBL3614471 | 0.82 | F10 (0.45) | F10KMT2AMAPTHTTSMN1; SMN2 | |
| SCHEMBL13546147 | 0.82 | MEN1 (0.41) | F10KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1997427 | 0.80 | F10 (0.65) | F10MAPTF2 | |
| SCHEMBL4664013 | 0.79 | LMNA (0.44) | F10KLKB1NT5EKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004292-A1 | Iminooxazolidine Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| WO-2007028520-A1 | IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004292-A1 | Iminooxazolidine Derivatives and Their Use | PPOX, XDH, PNPO | F10 152/4885KLKB1 1507/4885NAMPT 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.